| Pharmaceutical Information |
| Drug Name |
Voclosporin |
| Drug ID |
BADD_D02608 |
| Description |
Lupus nephritis (LN) is a type of glomerulonephritis occurring in patients with systemic lupus erythematosus (SLE). LN is a significant cause of renal failure, morbidity, and death in patients with SLE. Within 10 years of being diagnosed with SLE, 5-20% of those suffering from LN develop end-stage kidney disease, a fatal condition. Early and accurate intervention for LN is important in improving clinical outcomes.[A227683]
Voclosporin, marketed as Lupkynis, is a calcineurin-inhibitor immunosuppressant for the treatment of LN.[L31218] This [cyclosporine] A analog was approved by the FDA on January 22, 2021 following promising results in clinical trials. Early intervention with voclosporin coupled with a kidney response is believed to prevent irreversible damage to the kidney and lead to better long-term clinical outcomes for patients with LN.[L31208] Voclosporin has demonstrated a more stable pharmacokinetic and pharmacodynamic relationship than cyclosporine, a higher potency than cyclosporine, and an improved metabolic profile when compared to older calcineurin inhibitors.[L31253] |
| Indications and Usage |
Voclosporin is used in combination with a background immunosuppressive regimen for the treatment of lupus nephritis. Safety has not been established in combination with cyclophosphamide.[L31218] |
| Marketing Status |
approved; investigational |
| ATC Code |
L04AD03 |
| DrugBank ID |
DB11693
|
| KEGG ID |
D09033
|
| MeSH ID |
C484071
|
| PubChem ID |
6918486
|
| TTD Drug ID |
D0L9HX
|
| NDC Product Code |
47848-059; 11014-0480; 75626-001; 11014-0436; 49187-0803 |
| UNII |
2PN063X6B1
|
| Synonyms |
voclosporin | ISATX247 | ISA 247 | ISA-247 | ISA(TX)247 | lupkynis |
|
| Chemical Information |
| Molecular Formula |
C63H111N11O12 |
| CAS Registry Number |
515814-00-3 |
| SMILES |
CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C
(C(=O)N(C(C(=O)N1)C(C(C)CC=CC=C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C
)CC(C)C)C)C |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
